What Happened

TRex Bio priced a $117 million initial public offering, selling 8,333,334 shares at $14 each on the Nasdaq under ticker TRXB. The company develops drugs that treat immunological conditions by activating regulatory T cells (Tregs), with lead candidate TRB-061 in a Phase 1 trial and topline data expected in 2027. A second asset, TRB-071 for inflammatory bowel disease, could enter testing next year.

Who Is Affected

TRex Bio is now a publicly traded company, joining 23 biotech IPOs in 2026. Existing partners Eli Lilly (largest equity holder at ~24%) and Johnson & Johnson have licensed or exercised options to develop TRex-discovered anti-inflammatory drugs. Lilly also indicated interest in buying IPO shares, signaling continued involvement.

Market Impact

The IPO adds to a record surge in biotech public listings, with William Blair noting an 'unprecedented clip' in 2026. Over 25% of 2026 biotech IPOs are immune-disease focused, according to BioPharma Dive data. This trend expands the addressable market for life-sciences software vendors.

• TRex raised $117M at $14/share, meeting the lower end of its projection.
• Company has banked $220M in venture financing pre-IPO, including a $50M raise for the ongoing Phase 1 trial.
• Retension Pharmaceuticals also went public Thursday with an upsized $45M offering, highlighting market momentum.

What to Watch

Phase 1 data for TRB-061 in 2027 is a key catalyst; a positive readout could accelerate licensing discussions with Eli Lilly and Johnson & Johnson. As TRex scales clinical and operational infrastructure post-IPO, it will likely need upgraded compliance, regulatory, and clinical-trial management systems—an immediate sales trigger for life-sciences tech providers.

Related coverage

• TRex Bio and Retension Pharmaceuticals file for IPO; ADARx eyes up to $446M listing
• FDA approves Lilly's Jaypirca as first noncovalent BTK inhibitor for first-line CLL/SLL
• Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data
• Eli Lilly acquires 5-MeO-DMT developer AtaiBeckley for up to $3.8B